Angiotensin II type-I receptor antagonists in the treatment of heart failure

International Journal of Cardiology

Volumn 62, Issue SUPPL. 1, 1997, Pages

  Nicholls, M Gary ^a   Crozier, Ian G ^a   Ikram, Hamid ^a   Richards, A Mark ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

CONFERENCE PAPER; CORONARY HEMODYNAMICS; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HORMONE SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN;

EID: 0031467022     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00207-6     Document Type: Conference Paper

References (57)

1. Massie B.M., Shah N.B. The heart failure epidemic: magnitude of the problem and potential mitigating approaches. Curr Opinion Cardiol. 11:1996;221-226.
2. Reitsma J.B., Mosterd A., de Craen A.J.M.et al. Increase in hospital admission rates for heart failure in the Netherlands, 1980-1993. Heart. 76:1996;388-392.
3. Bonneux L., Looman C.W.N., Barendregt J.J., Van der Maas P.J. Regression analysis of recent changes in cardiovascular morbidity and mortality in the Netherlands. Br Med J. 314:1997;789-792.
4. Stewart A.L., Greenfield S., Hays R.D.et al. Functional status and well-being of patients with chronic conditions. J Am Med Assoc. 262:1989;907-913.
5. Levy D., Larson M.G., Vasan R.S., Kannel W.B., Ho K.K.L. The progression from hypertension to congestive heart failure. J Am Med Assoc. 275:1996;1557-1562.
6. McMumay J., Hart W., Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Economics. 6:1993;99-110.
7. Launois B., Reboul-Marty J., Battais J., Lefebvre P. Le coût de la sévérité de la maladie: le cas de l'insuffisance-cardiaque. J d'Economie Médicale. 8:1990;395-412.
8. Doughty R., Yee T., Sharpe N., MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand 1988-91. NZ Med J. 108:1995;473-475.
9. Vasan R.S., Benjamin F.J., Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 26:1995;1565-1574.
10. Ruzumna P., Gheorghiade M., Bonow R.O. Mechanisms and management of heart failure due to diastolic dysfunction. Curr Opinion Cardiol. 11:1996;269-275.
11. Nicholls M.G. Hypertension, hypertrophy, heart failure. Heart. 76(suppl.3):1996;92-97.
12. van Veldbuisen D.J., de Graeff P.A., Remme W.J., Lie K.I. Value of digoxin in heart failure and sinus rhythm: new features of an old drug? J Am Coll Cardiol. 28:1996;813-819.
13. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventriazlar ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
15. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
16. Yusuf S., Pepine C.J., Garces C.et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1992;1173-1178.
17. Pfeffer M.A., Braunwald E., Moyé L.A.et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 327:1992;669-677.
18. Campbell D.J. Angiotensin conventing enzyme (ACE) inhibitors and kinm metabolism: evidence that ACE inttibitors may inhibit a kininase other than ACE. Clin Exper Pharmacol Physiol. 22:1995;903-911.
19. Kiowski W., Beermann J., Rickenbacher P.et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converging enzyme inhibition in patients with chronic heart failure. Circulation. 90:1994;2748-2756.
20. Nussberger J, Brunner HR. Measurement of angiotensins in plasma. In: Robertson JIS, Nicholls MG eds. The Renin-angiotensin System. London: Gower Medical Publishing, 1993:15.1-15.13.
21. Urata H., Strobel F., Ganten D. Widespread tissue distribution of human chymase. J Hypertens. 12(suppl.9):1994;S17-S22.
22. Holt B.D., Shao Y., Kinoshita A., Gabel M., Husain A., Walsh R.A. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest. 95:1995;1519-1527.
23. Shiota N., Fukamizu A., Takai S., Okunishi H., Murakanv K., Miyazaki M. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J Hypertens. 15:1997;431-440.
24. 1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 92:1995;10663-10667.
25. Stoll M., Steckelings U.M., Paul M., Bottari S.P., Metzger R., Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 95:1995;651-657.
26. Ichiki T., Labosky P.A., Shiota C.et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 377:1995;748-750.
27. 1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography. Clin Exper Pharmacol Physiol. 21:1994;557-567.
28. 1-receptor antagonism in normal and heart-failed sheep. Am J Physiol. 269:1995;H425-H432.
29. Lacourcière Y., Brunner H., Irwin R.et al. Effects of modulators of the renin-angiotensin aldosterone system on cough. J Hypertens. 12:1994;1387-1393.
30. Raya T.E., Fonken S.J., Lee R.W.et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens. 4:1991;334S-340S.
31. Nishikimi T., Yamagishi H., Talseuchi K., Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res. 29:1995;856-861.
32. Qing G., Garcia R. Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure. Am J Physiol. 263:1992;H833-H840.
33. Yoshiyama M., Kim S., Yamagishi H.et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 128:1994;1-6.
34. Schieffer B., Wirger A., Meybrunn M.et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type I receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 89:1994;2273-2282.
35. Fitzpatrick M.A., Rademaker M.T., Charles C.J., Yandle T.G., Espiner E.A., Ikram H. Angiotensin II receptor antagonism in ovine heart failure: acute hemodynamic, hormonal, and renal effects. Am J Physiol. 263:1992;H250-H256.
36. Murakami M., Suzuki H., Naitoh M.et al. Blockade of the renin-angiotensin system in heart failure in conscious dogs. J Hypertens. 13:1995;1405-1412.
37. Kanda T., Araki M., Nakano M.et al. Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril. J Pharmacol Exper Ther. 273:1995;955-958.
38. 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 90:1994;3034-3046.
39. Ford W.R., Clanachan A.S., Jugdutt B.I. Opposite effects of angiotensin AT, and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation. 94:1996;3087-3089.
40. Milavetz J.J., Raya T.E., Johnson C.S., Morkin E., Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol. 27:1996;714-719.
41. Gottlieb S.S., Dickstein K., Fleck E.et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 88:1993;1602-1609.
42. Crozier I., Ikram H., Awan N.et al. Losartan in heart failure. Haemodynamic effects and tolerability. Circulation. 91:1995;691-697.
43. Dickstein K., Chang P., Willenheimer R.et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 26:1995;438-445.
44. Regitz-Zagrosek V., Neuss M., Holzmeister J., Fleck E. Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. J Hypertens. 13(suppl.1):1995;563-571.
45. Pitt B., Segal R., Martinez F.A.et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 349:1997;747-752.
46. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 5:1992;95-110.
47. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. J Am Med Assoc. 275:1996;1507-1513.
48. Himmelmann A., Svensson A., Bergbrant A., Hansson L. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Human Hypertens. 10:1996;729-734.
49. Azizi M., Chatellier G., Guyene T.-T., Murieta-Geoffroy D., Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin ll antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 92:1995;825-834.
50. Azizi M., Guyene T.-T., Chatellier G., Wargon M., Ménard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension. 29:1997;634-640.
51. Mukherjee R., Iannini J.P., Hebbar L.et al. Combined angiotensin converting enzyme inhibition and angiotensin II receptor blockade improve excitation-contraction coupling processes in the setting of congestive heart failure. Circulation. 94(Supp.I:abs.3207):1996.
52. Spinale F.G., de Gasparo M., Whitebread S.et al. The unique effects of combined angiotensin converting enzyme inhibition and angiotensin II receptor blockade on neurohormonal system activation and myocyte contractile processes with developing congestive heart failure. Circulation. 94(Supp.I):1996;2498.
53. Baruch L., Anand I.S., Judd D.L., Cohn J.N. Hemodynamic response to ATl receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure. Circulation. 94(Supp.I: abs.3207):1996.
54. Roques B.P., Noble F., Dauge V., Founve-Zaluski M.-C., Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 45:1993;87-146.
55. Trippodo N.C., Robl J.A., Asaad M.M.et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exper Ther. 275:1995;745-752.
56. Pham I., Gonzalez W., El Amrani A.-I.K.et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exper Ther. 265:1993;1339-1347.
57. Wong P.C., Duncia J.V., Chiu A.T.et al. EXPO63, a nonpeptide angiotensin II and beta adrenergic receptor antagonist. J Pharmacol Exper Ther. 267:1993;641-647.